KATP channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia-Reference-Cited by-同舟云学术

KATP channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia

Published:2002-10 Issue:7 Volume:40 Page:1339-1346
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Genda Satoshi,Miura Tetsuji,Miki Takayuki,Ichikawa Yoshihiko,Shimamoto Kazuaki

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference27 articles.

1. The ‘no-reflow’ phenomenon after temporary coronary occlusion in the dog;Kloner;J Clin Invest,1974

2. Does delayed no-reflow phenomenon cause myocardial necrosis?;Endoh;J Cardiovasc Pathol,1993

3. Clinical implications of the ‘no-reflow’ phenomenon;Ito;Circulation,1996

4. Relationship between progressive microvascular damage and intramyocardial hemorrhage in patients with reperfused anterior myocardial infarction. Myocardial contrast echocardiographic study;Asanuma;Circulation,1997

5. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction;Wu;Circulation,1998

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between four insulin resistance surrogates and left ventricular hypertrophy among hypertensive adults: a case–control study;Endocrine Connections;2024-02-01

2. Pinacidil ameliorates cardiac microvascular ischemia–reperfusion injury by inhibiting chaperone-mediated autophagy of calreticulin;Basic Research in Cardiology;2024-01-02

3. Merlot wine and the metabolic and cardiovascular changes in LDLR -/- mice;Ciência e Natura;2023-08-21

4. Hypercholesterolemia attenuates cardioprotection of ischemic preconditioning and postconditioning with α7 nicotinic acetylcholine receptor agonist by enhancing inflammation and inhibiting the PI3K/Akt/eNOS pathway;Experimental and Therapeutic Medicine;2022-03-22

5. INTRUSION OF GLYCOGEN SYNTHASE KINASE-3Β TO COPE VARIOUS CARDIAC DISORDERS AT MOLECULAR LEVEL;INDIAN DRUGS;2020-11-05